Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 16/498,104, filed Sep 26, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,034,772 | Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 11,396,553 | Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof In force · Low confidence | Genmab A/S | In force | Low confidence | ||
| US 11,512,137 | Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 12,577,316 | Methods of Use of ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies In force · Medium confidence | Genmab A/S | In force | Medium confidence | ||
| US 12,448,459 | Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof In force · Medium confidence | Genmab A/S | In force | Medium confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.